The Renin-Angiotensin System (RAS) is frequently conceptualized as a simple, linear hormonal cascade responsible for regulating blood pressure and fluid balance. However, modern vascular biology reveals that RAS actually functions as a delicate biochemical seesaw. On one side sits a destructive, pro-inflammatory pathway; on the other sits a protective, counter-regulatory arm. When this seesaw tips, the resulting biochemical imbalance drives severe tissue injury across multiple organ systems, acting as a common pathological engine for viral infections, environmental toxins, and chronic metabolic diseases.
The Two Arms of the Seesaw
To understand why RAS imbalances are so destructive, we must first look at the two opposing forces that maintain homeostatic equilibrium:
- The ACE-Ang II-AT1R Axis: This is the body's emergency response arm. Angiotensin-Converting Enzyme (ACE) cleaves Angiotensin I into Angiotensin II (Ang II), a potent peptide that binds to the AT1 receptor (AT1R). While essential for acute stress responses, chronic or excessive activation of this axis triggers vasoconstriction, oxidative stress, cellular apoptosis, and progressive tissue fibrosis.
- The ACE2-Ang(1-7)-Mas Axis: This is the essential brake system. Angiotensin-Converting Enzyme 2 (ACE2) counteracts the destructive arm by directly degrading the toxic Ang II into Angiotensin-(1-7). This cleaved peptide binds to the Mas receptor, triggering downstream signaling pathways—such as endothelial nitric oxide synthase (eNOS) phosphorylation—that promote vasodilation, suppress inflammation, and protect cellular integrity.
Under healthy conditions, these two axes balance each other perfectly. Tissue injury occurs when the protective brake (ACE2) is removed or overridden, leaving the destructive acceleration of Ang II completely unchecked.
[ ACE-Ang II-AT1R ] <--- Seesaw ---> [ ACE2-Ang(1-7)-Mas ]
(Vasoconstriction, Fibrosis) (Vasodilation, Protection)
How the Balance Breaks
The protective ACE2 brake can be compromised by remarkably diverse triggers, ranging from microscopic pathogens to synthetic engineered materials.
Viral Exploitation and Receptor Depletion
The most prominent real-world demonstration of this imbalance occurs during viral infections. As detailed by Li et al., pathogens like SARS-CoV-2 utilize the cell-surface ACE2 receptor as their primary entry point into host cells. When the virus binds to ACE2, the receptor is internalized and downregulated.
This viral entry mechanism causes a severe, localized depletion of functional surface ACE2. As a result, the tissue loses its ability to degrade Ang II. As Ji et al. observed, this sudden accumulation of unmitigated Ang II acts as a molecular trigger that can ignite systemic hyper-inflammatory cascades and cytokine storms.
Chemical and Nanoparticle Inhibition
This regulatory disruption is not unique to viral biology. Work by Sun et al. uncovered a molecular "smoking gun" demonstrating that cationic nanoparticles—such as PAMAM dendrimers used in targeted drug delivery—directly bind to and physically inhibit the ACE2 enzyme. By blocking the active site of ACE2, these nanomaterials cause a rapid, non-viral accumulation of Ang II, triggering acute lung failure through severe vascular leakage and localized inflammation.
Chronic and Metabolic Pre-Tilting
In other instances, the seesaw is already dangerously tilted before an acute insult even arrives. Investigating a high-fidelity animal model, Ziegler et al. found that metabolic syndrome inherently shifts the baseline cardiac RAS toward a pro-inflammatory state by significantly increasing the ratio of ACE to the protective ACE2 enzyme.
Conversely, chronic inflammatory conditions can attack the equilibrium from the opposite direction. In a comparative review, Zhao et al. noted that while viruses downregulate ACE2, chronic granulomatous diseases like sarcoidosis feature inflammatory granulomas that actively overproduce ACE. Despite their completely different etiologies, both pathways converge on the exact same destructive endpoint: a massive, unchecked accumulation of Ang II.
The Multi-Organ Domino Effect
When ACE2 is depleted or inhibited, the resulting surge in Ang II causes a predictable wave of destruction across the body's most vascularized organs.
- The Lungs: Unchecked Ang II drives severe pulmonary vasoconstriction and endothelial barrier breakdown. This leads directly to the fluid accumulation, pulmonary edema, and aggressive tissue remodeling characteristic of acute lung injury (Zhao et al.).
- The Heart: In the myocardium, the loss of the ACE2-Ang(1-7) axis allows Ang II to drive pro-apoptotic and pro-fibrotic signaling, accelerating detrimental cardiac remodeling and localized tissue damage (Tie et al.; Li et al.).
- The Kidneys: The renal system is highly sensitive to perfusion changes. As Wang et al. explained, viral binding and subsequent downregulation of renal ACE2 receptors trigger localized vasoconstriction and oxidative stress. This severely compromises renal blood flow, making RAS dysregulation a primary driver of acute kidney injury in critically ill patients (Gabarre et al.).
Systemic Electrolyte Wasting
Because RAS is intimately tied to the broader aldosterone system, this localized tissue imbalance quickly spills over into systemic metabolic chemistry. When Ang II levels surge unchecked, it hyperactivates downstream mineralocorticoid pathways in the kidneys, forcing the body to abnormally excrete vital electrolytes.
This specific mechanism explains a well-documented clinical phenomenon: patients suffering from severe receptor-mediated RAS disruption frequently present with profound hypokalemia (low serum potassium), which correlates heavily with poor clinical outcomes (Yin et al.). Similarly, this hyperactivation disrupts renal acid-base handling, causing abnormal bicarbonate retention that serves as a distinct clinical marker of systemic regulatory failure (Sada et al.).
Restoring the Equilibrium
Because the core pathology is a structural imbalance between two opposing pathways, effective therapeutic strategies focus on pushing the seesaw back toward equilibrium. This can be achieved either by dampening the destructive axis or actively reinforcing the protective one.
[ Therapeutic Interventions ]
|-- Block ACE / Ang II / AT1R (e.g., Fraxinol)
|-- Boost ACE2 Expression (e.g., C/EBPβ)
`-- Activate Mas Receptor / eNOS (e.g., Propofol)
One approach involves targeting the transcription factors that dictate how many protective "brakes" the body produces. For example, Tie et al. demonstrated that overexpressing the transcription factor C/EBPβ directly upregulates endogenous ACE2 expression, successfully counteracting Ang II-driven myocardial remodeling.
Alternatively, exogenous compounds can be introduced to re-balance both axes simultaneously. Wu et al. showed that the natural coumarin compound fraxinol mitigates acute lung injury precisely because it acts as a dual-action regulator: it dampens the hyperactive ACE-Ang II-AT1R axis while actively reinforcing the protective ACE2-Ang(1-7)-Mas axis.
Even widely used clinical agents can be leveraged for their hidden balancing properties. Zhang et al. discovered that the common anesthetic propofol directly protects endothelial cells from Ang II-induced apoptosis. It achieves this by actively triggering eNOS phosphorylation and turning on the protective signaling cascades of the ACE2-Ang(1-7)-Mas axis.
Ultimately, whether treating a viral infection, a chronic metabolic condition, or nanoparticle toxicity, the underlying therapeutic mandate remains the same: to rescue the tissue, one must restore the balance of the renin-angiotensin seesaw.
Key Foundational Work
<scp>CCAAT</scp>/enhancer‐binding protein β overexpression alleviates myocardial remodelling by regulating angiotensin‐converting enzyme‐2 expression in diabetes (2017) — contributed 1 concept elements to this direction.
Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice (2015) — contributed 1 concept elements to this direction.